ASH 2024 – Shirley D’Sa

You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content

Shirley D’Sa highlights the ASPEN trial’s key insights on durable responses with zanubrutinib monotherapy in Waldenström’s macroglobulinemia, explores promising results for the radiopharmaceutical iopofosine in pretreated patients, and shares real-world data from the global registry WhiMSICAL on how therapies impact patients’ quality of life.

Here is the full ASH 2024 report.